A Voxelotor for Sickle Cell Anemia Patients at Highest Risk for Progression of Chronic Kidney Disease
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Sickle Cell Disease
- Sickle Cell Nephropathy
- Type
- Interventional
- Phase
- Phase 1Phase 2
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentIntervention Model Description: 6 participants will take voxelotor 1500mg once a day 6 participants will be observed while receiving standard of care (SOC)Masking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
This study is a single center, prospective exploratory pilot study of Sickle Cell Anemia (SCA) participants, age ?18 years, with SCA. The study will enroll patients with early stages of sickle cell nephropathy (Chronic Kidney Disease (CKD) stage 1 or 2) who are at the highest risk of CKD progression...
This study is a single center, prospective exploratory pilot study of Sickle Cell Anemia (SCA) participants, age ?18 years, with SCA. The study will enroll patients with early stages of sickle cell nephropathy (Chronic Kidney Disease (CKD) stage 1 or 2) who are at the highest risk of CKD progression (presence of both hemoglobinuria and urine albumin concentration ? 30 mg/g creatinin
Tracking Information
- NCT #
- NCT04335721
- Collaborators
- Global Blood Therapeutics
- Investigators
- Not Provided
Get Well Soon